Immuron Limited published an Appendix 3H notification to the Australian Securities Exchange on June 18, 2026, regarding the cessation of securities. The filing serves as an explanatory note for the public notice attached as an exhibit. Immuron Limited is a biotechnology company focused on developing immunotherapies.
